California State Teachers Retirement System Increases Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM

California State Teachers Retirement System raised its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 22.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,476 shares of the company’s stock after acquiring an additional 8,065 shares during the quarter. California State Teachers Retirement System’s holdings in Mirum Pharmaceuticals were worth $4,109,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of MIRM. Cullen Frost Bankers Inc. acquired a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth about $30,000. Eurizon Capital SGR S.p.A. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $32,000. CIBC Private Wealth Group LLC purchased a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $32,000. Quantbot Technologies LP acquired a new stake in Mirum Pharmaceuticals during the 3rd quarter worth approximately $33,000. Finally, Comerica Bank boosted its position in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 1,840 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $105.29, for a total value of $193,733.60. Following the transaction, the senior vice president directly owned 1,274 shares in the company, valued at $134,139.46. This represents a 59.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $122.25, for a total transaction of $611,250.00. Following the sale, the chief financial officer owned 42,181 shares of the company’s stock, valued at $5,156,627.25. This represents a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 67,155 shares of company stock valued at $7,185,662. Corporate insiders own 8.32% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on MIRM. JPMorgan Chase & Co. boosted their price target on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, July 2nd. Citizens Jmp decreased their target price on Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating for the company in a report on Thursday. Robert W. Baird set a $123.00 target price on Mirum Pharmaceuticals in a research note on Thursday. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Thursday. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $165.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $137.33.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $100.65 on Friday. Mirum Pharmaceuticals, Inc. has a twelve month low of $57.79 and a twelve month high of $130.00. The firm’s fifty day simple moving average is $110.33 and its 200-day simple moving average is $101.79. The firm has a market capitalization of $6.14 billion, a price-to-earnings ratio of -6.92 and a beta of 0.52. The company has a current ratio of 2.86, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The business had revenue of $176.24 million during the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same period last year, the company earned ($0.12) EPS. Equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue reached $176.24 million, beating the $166.33 million consensus estimate and rising 37.9% year over year. Growth was driven by Livmarli and Mirum’s other bile-acid therapies. Management also raised its 2026 sales outlook, providing a favorable signal about demand and the company’s commercial trajectory. Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts remain broadly constructive despite reducing their targets. TD Cowen lowered its target to $140 and retained a “buy” rating; Citizens JMP cut its target to $137 but maintained “market outperform”; and HC Wainwright reduced its target to $140 while keeping a “buy” rating. These targets imply substantial potential upside from recent trading levels.
• Neutral Sentiment: Mirum reported a quarterly loss of $1.06 per share, wider than the $0.74 consensus loss and the $0.12 loss recorded a year earlier. The loss reflects continued investment in the company’s rare-disease pipeline, but it remains a near-term valuation concern. Mirum’s Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
• Negative Sentiment: Citizens warned that an “unexpected” FDA request for a Phase 3 study clouds Mirum’s near-term outlook. The additional regulatory requirement could delay development or approval plans, increase spending, and weigh on investor sentiment.
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734, reducing her direct holdings by 59.1%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which lessens its signaling value, but the sale still adds a modest negative headline.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.